Which item is an example of 'Other Observations' in expedited reporting?

• A. A major safety finding from a newly completed animal study.
• B. A mild rash that is expected.
• C. An increase in the rate of occurrence for an 'expected' serious ADR judged clinically important.
• D. A nonclinical pharmacokinetic anomaly.

Answer: (C)

In expedited safety reporting, there are two main categories: SUSARs (serious and unexpected adverse reactions) and Other Observations (OSI), which covers safety information that doesn’t meet SUSAR criteria but is important for patient safety. An increase in how often a known serious adverse reaction occurs is exactly the kind of safety signal that belongs in OSI. It doesnures regulators that the risk profile may be changing and warrants prompt review, even though the event itself isn’t new.

The other options don’t fit as OSI: a major safety finding from animal studies is nonclinical data and not a human safety event requiring expedited reporting; a mild rash that’s expected isn’t a new or clinically important signal; a nonclinical pharmacokinetic anomaly isn’t a safety observation from participants in the trial.